Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
November 29, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
November 28, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily Rezafungin PDUFA target action date is scheduled for March 22, 2023 SAN DIEGO...
Cidara Therapeutics to Participate in the World Antiviral Congress 2022
November 23, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics to Present at the Stifel Healthcare Conference
November 08, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 03, 2022 17:47 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
October 17, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
October 04, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin Company eligible to receive up to an additional $108M in milestones from...
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
September 20, 2022 16:05 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
September 13, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention Study is being conducted in...
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
September 06, 2022 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...